학술논문
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Document Type
Article
Author
Paz-Ares, Luis; Champiat, Stephane; Lai, W. Victoria; Izumi, Hiroki; Govindan, Ramaswamy; Boyer, Michael; Hummel, Horst-Dieter; Borghaei, Hossein; Johnson, Melissa L.; Steeghs, Neeltje; Blackhall, Fiona; Dowlati, Afshin; Reguart, Noemi; Yoshida, Tatsuya; He, Kai; Gadgeel, Shirish M.; Felip, Enriqueta; Zhang, Yiran; Pati, Amrita; Minocha, Mukul
Source
Journal of Clinical Oncology; 6/1/2023, Vol. 41 Issue 16, p2893-2903, 11p
Subject
Language
ISSN
0732183X